(Stroke. 1996;27:1453-1458.)
© 1996 American Heart Association, Inc.
Articles |
A Randomized Trial of Tirilazad Mesylate in Patients With Acute Stroke (RANTTAS)
the Departments of Neurology and Neurological Surgery, The Virginia Neurological Institute of the University of Virginia (Charlottesville) (Dr Haley, Dr Johnston, and others), and the participating centers of the RANTTAS Investigators.
Correspondence to E. Clarke Haley, Jr, MD, Department of Neurology, Box 394, University of Virginia Health Sciences Center, Charlottesville, VA 22908. E-mail ech@virginia.edu.
Background and Purpose Tirilazad mesylate, a nonglucocorticoid 21-aminosteroid lipid peroxidation inhibitor, has shown promise as a neuroprotectant in experimental models of focal cerebral ischemia.
Methods To test whether early treatment with tirilazad, 6 mg/kg per day for 3 days, would improve functional outcome after acute human stroke, 27 North American centers conducted a prospective, randomized, double-blinded, vehicle-controlled trial in patients with acute stroke treated within 6 hours of onset. The primary outcome measures were disability as measured by the Glasgow Outcome Scale and activities of daily living by the Barthel Index determined 3 months after stroke.
Results From May 1993 through December 1994, 660 patients were randomized. The trial was prematurely terminated on the advice of an independent monitoring committee after review of outcome data at a preplanned interim analysis. In 556 fully eligible patients (276 tirilazad, 280 vehicle), the odds ratio of a favorable outcome in favor of tirilazad was 0.87 (95% confidence interval [CI], 0.60 to 1.25) for the Glasgow Outcome Scale and 0.87 (95% CI, 0.60 to 1.25) for the Barthel Index, after adjustment for imbalances between the groups in preexisting disability, prior stroke, and diabetes.
Conclusions These observations suggest that tirilazad, 6 mg/kg per day for 3 days administered beginning at a median of 4.3 hours after stroke, does not improve overall functional outcome.
Key Words: cerebral ischemia • lipid peroxidation • neuroprotection • stroke, acute
This article has been cited by other articles:
 |
|
 |
|
  P. Mandava and T. A. Kent A Method to Determine Stroke Trial Success Using Multidimensional Pooled Control Functions Stroke, May 1, 2009; 40(5): 1803 - 1810. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Altamura, R. Squitti, P. Pasqualetti, C. Gaudino, P. Palazzo, F. Tibuzzi, D. Lupoi, M. Cortesi, P. M. Rossini, and F. Vernieri Ceruloplasmin/Transferrin System Is Related to Clinical Status in Acute Stroke Stroke, April 1, 2009; 40(4): 1282 - 1288. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The Optimising the Analysis of Stroke Trials (OAST Should Stroke Trials Adjust Functional Outcome for Baseline Prognostic Factors? Stroke, March 1, 2009; 40(3): 888 - 894. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Ginsberg Current Status of Neuroprotection for Cerebral Ischemia: Synoptic Overview Stroke, March 1, 2009; 40(3_suppl_1): S111 - S114. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Johnston The 2008 William M. Feinberg Lecture: Prioritizing Stroke Research Stroke, December 1, 2008; 39(12): 3431 - 3436. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Marler NINDS Clinical Trials in Stroke: Lessons Learned and Future Directions Stroke, December 1, 2007; 38(12): 3302 - 3307. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Sakellaridis and D. Panagopoulos Significance of Experimental Infarct Size as an Indicator of Therapeutic Efficacy in Humans Stroke, September 1, 2007; 38(9): e89 - e90. [Full Text] [PDF]
|
|
|
|
|
|
The Optimising Analysis of Stroke Trials (OAST) Co Can We Improve the Statistical Analysis of Stroke Trials?: Statistical Reanalysis of Functional Outcomes in Stroke Trials * OAST Supplemental Appendix I: Statistical Tests Compared (see Table I) * OAST Supplemental Appendix II: Supplementary Analyses * OAST Supplemental Appendix III: Trial Data (see Tables II and III) * OAST Supplemental Appendix IV: Results (see Table IV) Stroke, June 1, 2007; 38(6): 1911 - 1915. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Ginsberg Life After Cerovive: A Personal Perspective on Ischemic Neuroprotection in the Post-NXY-059 Era Stroke, June 1, 2007; 38(6): 1967 - 1972. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. P. Adams Jr, G. del Zoppo, M. J. Alberts, D. L. Bhatt, L. Brass, A. Furlan, R. L. Grubb, R. T. Higashida, E. C. Jauch, C. Kidwell, et al. Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation, May 22, 2007; 115(20): e478 - e534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. P. Adams Jr, G. del Zoppo, M. J. Alberts, D. L. Bhatt, L. Brass, A. Furlan, R. L. Grubb, R. T. Higashida, E. C. Jauch, C. Kidwell, et al. Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/ American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists Stroke, May 1, 2007; 38(5): 1655 - 1711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Hachinski Stroke and Vascular Cognitive Impairment: A Transdisciplinary, Translational and Transactional Approach Stroke, April 1, 2007; 38(4): 1396 - 1396. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Elkins, T. Khatabi, L. Fung, J. Rootenberg, and S. C. Johnston Recruiting Subjects for Acute Stroke Trials: A Meta-Analysis Stroke, January 1, 2006; 37(1): 123 - 128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Y. Palesch, B. C. Tilley, D. L. Sackett, K. C. Johnston, and R. Woolson Applying a Phase II Futility Study Design to Therapeutic Stroke Trials Stroke, November 1, 2005; 36(11): 2410 - 2414. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. B. Young, C. J. Weir, K. R. Lees, and for the GAIN International Trial Steering Committe Comparison of the National Institutes of Health Stroke Scale With Disability Outcome Measures in Acute Stroke Trials Stroke, October 1, 2005; 36(10): 2187 - 2192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Warner, H. Sheng, and I. Batinic-Haberle Oxidants, antioxidants and the ischemic brain J. Exp. Biol., August 15, 2004; 207(18): 3221 - 3231. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Weaver, J. Leonardi-Bee, F. J. Bath-Hextall, and P. M.W. Bath Sample Size Calculations in Acute Stroke Trials: A Systematic Review of Their Reporting, Characteristics, and Relationship With Outcome Stroke, May 1, 2004; 35(5): 1216 - 1224. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kwon, A. G. Hartzema, P. W. Duncan, and S. Min-Lai Disability Measures in Stroke: Relationship Among the Barthel Index, the Functional Independence Measure, and the Modified Rankin Scale Stroke, April 1, 2004; 35(4): 918 - 923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. C. Johnston, A. F. Connors Jr, D. P. Wagner, and E. C. Haley Jr Risk Adjustment Effect on Stroke Clinical Trials Stroke, February 1, 2004; 35 (2): e43 - e45. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Zausinger, K. Scholler, N. Plesnila, and R. Schmid-Elsaesser Combination Drug Therapy and Mild Hypothermia After Transient Focal Cerebral Ischemia in Rats Stroke, September 1, 2003; 34(9): 2246 - 2251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. P. Adams Jr, R. J. Adams, T. Brott, G. J. del Zoppo, A. Furlan, L. B. Goldstein, R. L. Grubb, R. Higashida, C. Kidwell, T. G. Kwiatkowski, et al. Guidelines for the Early Management of Patients With Ischemic Stroke: A Scientific Statement From the Stroke Council of the American Stroke Association Stroke, April 1, 2003; 34(4): 1056 - 1083. [Full Text] [PDF]
|
|
|
|
|
|
K. C. Johnston, A. F. Connors Jr, D. P. Wagner, and E. C. Haley Jr Predicting Outcome in Ischemic Stroke: External Validation of Predictive Risk Models Stroke, January 1, 2003; 34(1): 200 - 202. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Mocco, T. Choudhri, J. Huang, E. Harfeldt, L. Efros, C. Klingbeil, V. Vexler, W. Hall, Y. Zhang, W. Mack, et al. HuEP5C7 as a Humanized Monoclonal Anti-E/P-Selectin Neurovascular Protective Strategy in a Blinded Placebo-Controlled Trial of Nonhuman Primate Stroke Circ. Res., November 15, 2002; 91(10): 907 - 914. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. C. Johnston, D. P. Wagner, E. C. Haley Jr, and A. F. Connors Jr Combined Clinical and Imaging Information as an Early Stroke Outcome Measure Stroke, February 1, 2002; 33(2): 466 - 472. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Sacco, J. T. DeRosa, E. C. Haley Jr, B. Levin, P. Ordronneau, S. J. Phillips, T. Rundek, R. G. Snipes, J. L. P. Thompson, and for the GAIN Americas Investigators Glycine Antagonist in Neuroprotection for Patients With Acute Stroke: GAIN Americas: A Randomized Controlled Trial JAMA, April 4, 2001; 285(13): 1719 - 1728. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Uchino, D. Billheimer, and S. C. Cramer Entry Criteria and Baseline Characteristics Predict Outcome in Acute Stroke Trials Stroke, April 1, 2001; 32(4): 909 - 916. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. P. Samsa and D. B. Matchar Have Randomized Controlled Trials of Neuroprotective Drugs Been Underpowered? : An Illustration of Three Statistical Principles Stroke, March 1, 2001; 32(3): 669 - 674. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. R. Lees, A. K. Sharma, D. Barer, G. A. Ford, V. Kostulas, Y.-F. Cheng, and T. Odergren Tolerability and Pharmacokinetics of the Nitrone NXY-059 in Patients With Acute Stroke Stroke, March 1, 2001; 32(3): 675 - 680. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Kavanagh and P. C. A. Kam Lazaroids: efficacy and mechanism of action of the 21-aminosteroids in neuroprotection Br. J. Anaesth., January 1, 2001; 86(1): 110 - 119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Fisher and W. Schaebitz An Overview of Acute Stroke Therapy: Past, Present, and Future Arch Intern Med, November 27, 2000; 160(21): 3196 - 3206. [Full Text] [PDF]
|
|
|
|
|
|
H. C. Diener, M. Cortens, G. Ford, J. Grotta, W. Hacke, M. Kaste, P. J. Koudstaal, and T. Wessel Lubeluzole in Acute Ischemic Stroke Treatment : A Double-Blind Study With an 8-Hour Inclusion Window Comparing a 10-mg Daily Dose of Lubeluzole With Placebo Stroke, November 1, 2000; 31(11): 2543 - 2551. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Delanty and M. A. Dichter Antioxidant Therapy in Neurologic Disease Arch Neurol, September 1, 2000; 57(9): 1265 - 1270. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Tirilazad Mesylate in Acute Ischemic Stroke : A Systematic Review Stroke, September 1, 2000; 31(9): 2257 - 2265. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. E. Mayer, G. F. Hamann, J. Baranczyk, B. Rosengarten, E. Klotz, M. Wiesmann, U. Missler, G. Schulte-Altedorneburg, and H. J. Brueckmann Dynamic CT Perfusion Imaging of Acute Stroke AJNR Am. J. Neuroradiol., August 1, 2000; 21(8): 1441 - 1449. [Abstract] [Full Text]
|
|
|
|
|
|
K. C. Johnston, A. F. Connors Jr, D. P. Wagner, W. A. Knaus, X.-Q. Wang, and E. C. Haley Jr A Predictive Risk Model for Outcomes of Ischemic Stroke Stroke, February 1, 2000; 31(2): 448 - 455. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G DEVUYST and J BOGOUSSLAVSKY Recent progress in drug treatment for acute stroke J. Neurol. Neurosurg. Psychiatry, October 1, 1999; 67(4): 420 - 425. [Full Text] [PDF]
|
|
|
|
|
|
R. Schmid-Elsaesser, E. Hungerhuber, S. Zausinger, A. Baethmann, H.-J. Reulen, and J. A. Zivin Combination Drug Therapy and Mild Hypothermia : A Promising Treatment Strategy for Reversible, Focal Cerebral Ischemia • Editorial Comment: A Promising Treatment Strategy for Reversible, Focal Cerebral Ischemia Stroke, September 1, 1999; 30 (9): e1891 - 1899. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Davis and D. Barer Neuroprotection in acute ischaemic stroke. II: Clinical potential Vascular Medicine, August 1, 1999; 4(3): 149 - 163. [Abstract] [PDF]
|
|
|
|
|
|
G. Sulter, C. Steen, and Jacques De Keyser Use of the Barthel Index and Modified Rankin Scale in Acute Stroke Trials Stroke, August 1, 1999; 30(8): 1538 - 1541. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. DeGraba, J. M. Hallenbeck, K. D. Pettigrew, A. J. Dutka, and B. J. Kelly Progression in Acute Stroke : Value of the Initial NIH Stroke Scale Score on Patient Stratification in Future Trials Stroke, June 1, 1999; 30(6): 1208 - 1212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Berrouschot, H. Barthel, J. Koster, S. Hesse, A. Rossler, W. H. Knapp, and D. Schneider Extracorporeal Rheopheresis in the Treatment of Acute Ischemic Stroke : A Randomized Pilot Study Stroke, April 1, 1999; 30(4): 787 - 792. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Saver, K. C. Johnston, D. Homer, R. Wityk, W. Koroshetz, L. L. Truskowski, and E. C. Haley Infarct Volume as a Surrogate or Auxiliary Outcome Measure in Ischemic Stroke Clinical Trials Stroke, February 1, 1999; 30(2): 293 - 298. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. C. Haley Jr High-Dose Tirilazad for Acute Stroke (RANTTAS II) Stroke, June 1, 1998; 29 (6): 1256 - 1257. [Full Text]
|
|
|
|
|
|
M. Fisher and J. Bogousslavsky Further Evolution Toward Effective Therapy for Acute Ischemic Stroke JAMA, April 22, 1998; 279(16): 1298 - 1303. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. C. Johnston, J. Y. Li, P. D. Lyden, S. K. Hanson, T. E. Feasby, R. J. Adams, R. E. Faught Jr, and E. C. Haley Jr Medical and Neurological Complications of Ischemic Stroke : Experience From the RANTTAS Trial Stroke, February 1, 1998; 29(2): 447 - 453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. G. Dyker and K. R. Lees Duration of Neuroprotective Treatment for Ischemic Stroke Stroke, February 1, 1998; 29(2): 535 - 542. [Abstract] [Full Text] [PDF]
|
|